Finally, we reasoned that if a higher rate of apoptosis is responsible for the reduced tumorigenic properties observed upon USP22 loss in HER2+-BC, the inhibition of caspase activity should, at least partially, rescue the impaired phenotype. The gene discussed is USP22; the disease is breast cancer.